NDA 021151 · Legacy
Betapace Af
Sotalol Hydrochloride · Oral
OrphanLast checked: Nov 20, 2026Latest source record: Aug 17, 2011 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Feb 22, 2000
Approved uses
1
Original approval plus efficacy supplements
Registered trials
57
14 Phase 3, 9 recruiting
FAERS reports
2,600
2,156 serious, 260 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
6 products under this application
- BETAPACE AF · SOTALOL HYDROCHLORIDE 40MG · TABLET, ORAL · Discontinued
- BETAPACE AF · SOTALOL HYDROCHLORIDE 120MG · TABLET, ORAL · Prescription · TE AB
- BETAPACE AF · SOTALOL HYDROCHLORIDE 60MG · TABLET, ORAL · Discontinued
- BETAPACE AF · SOTALOL HYDROCHLORIDE 100MG · TABLET, ORAL · Discontinued
- BETAPACE AF · SOTALOL HYDROCHLORIDE 160MG · TABLET, ORAL · Prescription · TE AB
- BETAPACE AF · SOTALOL HYDROCHLORIDE 80MG · TABLET, ORAL · Prescription · TE AB
Clinical trials
Interventional ClinicalTrials.gov studies with "Sotalol" as an intervention, any sponsor and status, largest first.
- Catheter Ablation vs Anti-arrhythmic Drug Therapy for Atrial Fibrillation TrialPivotal-lookingCompleted
Mayo ClinicAcademic, hospital or other
NCT00911508 · 2,204 participants · Start Nov 13, 2009 · Primary completion Dec 31, 2017
Drug: Rate or Rhythm Control Therapy · For: Atrial Fibrillation; Arrhythmia
Sites: Little Rock, Arkansas; Los Angeles, California; Sacramento, California · 118 sites in all
- Kansai Plus Atrial Fibrillation TrialPivotal-lookingCompleted
Kyoto University, Graduate School of MedicineAcademic, hospital or other
NCT01477983 · 2,113 participants · Start Nov 2011 · Primary completion Jul 2017
Drug: Antiarrhythmic drug (AAD); Control and 2 more · For: Atrial Fibrillation
Sites: Kyoto, Japan
Assistance Publique - Hôpitaux de ParisAcademic, hospital or other
NCT00773201 · 997 participants · Start Feb 2008 · Primary completion Mar 2012
Drug: Sotalol 80 mg · For: Healthy Volunteers
Sites: Paris, France
- Flecainide Safety in Patients With Coronary Artery Disease and Atrial FibrillationPivotal-lookingRecruiting
Universitaire Ziekenhuizen KU LeuvenAcademic, hospital or other
NCT07405671 · 988 participants (planned) · Start Sep 2026 · Primary completion Dec 2029
Drug: flecainide; Sotalol or Amiodarone · For: Atrial Fibrillation (AF); Coronary Artery Disease
Sites: Aalst, Belgium; Bonheiden, Belgium; Bruges, Belgium · 14 sites in all
- Comparing the Effects of Amiodarone, Sotalol, and Placebo in Maintaining Sinus Rhythm in Patients With Atrial Fibrillation Converted to Sinus RhythmPivotal-lookingCompleted
US Department of Veterans AffairsFederal agency
NCT00007605 · 706 participants (planned) · Start Apr 1998 · Primary completion Oct 2002
Drug: Amiodarone; Sotalol · For: Atrial Fibrillation; Cerebrovascular Accident; Death, Sudden
Sites: Tucson, Arizona; No. Little Rock, Arkansas; Fresno, California · 28 sites in all
- Efficacy and Safety Evaluation of Azimilide or Sotalol vs Placebo for Treatment of Patients With Atrial Fibrillation.Pivotal-lookingCompleted
Forest LaboratoriesAbbVie (ABBV)
NCT00035451 · 658 participants · Start Feb 2001 · Primary completion Jun 2003
Drug: Azimilide Dihydrochloride; Placebo and 1 more · For: Atrial Fibrillation
Sites: Brussels, Belgium; Yvoir, Belgium; Aix-en-Provence, France · 129 sites in all
- Antiarrhythmic Drugs Assessment in Preventing Atrial FibrillationPivotal-lookingStatus unknown
Xinhua Hospital, Shanghai Jiao Tong University School of MedicineAcademic, hospital or other
NCT02145546 · 600 participants (planned) · Start May 2014 · Primary completion May 2017
Drug: Amiodarone; Propafenone and 1 more · For: Atrial Fibrillation
Sites: Shanghai, China
- Efficacy of Early Rhythm Control Therapy in Patients With Subclinical Atrial FibrillationPivotal-lookingRecruiting
Samsung Medical CenterAcademic, hospital or other
NCT07447297 · 520 participants (planned) · Start Jan 2, 2024 · Primary completion Dec 15, 2027
Drug: early rhythm control group · For: Atrial Fibrillation (AF); Diseases of the Circulatory System; Atrial Flutter
Sites: Seoul, South Korea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- atrial fibrillation186
- drug ineffective151
- electrocardiogram qt prolonged149
- hypotension125
- dyspnoea119
- dizziness116
- bradycardia112
- drug interaction99
- fatigue97
- nausea95
- fall87
- off label use73
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 53 |
| 2005 | 32 |
| 2006 | 128 |
| 2007 | 237 |
| 2008 | 43 |
| 2009 | 128 |
| 2010 | 36 |
| 2011 | 90 |
| 2012 | 111 |
| 2013 | 63 |
| 2014 | 70 |
| 2015 | 56 |
| 2016 | 80 |
| 2017 | 98 |
| 2018 | 124 |
| 2019 | 147 |
| 2020 | 112 |
| 2021 | 95 |
| 2022 | 142 |
| 2023 | 152 |
| 2024 | 194 |
| 2025 | 254 |
| 2026 | 155 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Betapace Af (Sotalol HCl)
2024 spending
$199K
Beneficiaries
23
112 claims
Per beneficiary
$8,658
$14.97 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $432,548 |
| 2021 | $295,085 |
| 2022 | $237,965 |
| 2023 | $224,275 |
| 2024 | $199,124 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment for beta-blocker poisoning: a systematic review.
Rotella JA, Greene SL, Koutsogiannis Z, et al. · Clin Toxicol (Phila) 2020 · Systematic Review
- Catheter Ablation or Antiarrhythmic Drugs for Ventricular Tachycardia.
Sapp JL, Tang ASL, Parkash R, et al. · N Engl J Med 2025 · Clinical Trial, Phase IV, Comparative Study
- Intravenous Flecainide for Emergency Department Management of Acute Atrial Fibrillation.
Markey GC, Salter N, Ryan J · J Emerg Med 2018 · Meta-Analysis, Systematic Review
- Substrate Ablation vs Antiarrhythmic Drug Therapy for Symptomatic Ventricular Tachycardia.
Arenal Á, Ávila P, Jiménez-Candil J, et al. · J Am Coll Cardiol 2022 · Multicenter Study, Randomized Controlled Trial
- Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.
Lafuente-Lafuente C, Valembois L, Bergmann JF, et al. · Cochrane Database Syst Rev 2015 · Meta-Analysis, Research Support, Non-U.S. Gov't
- External electrical and pharmacological cardioversion for atrial fibrillation, atrial flutter or atrial tachycardias: a network meta-analysis.
Kukendrarajah K, Ahmad M, Carrington M, et al. · Cochrane Database Syst Rev 2024 · Systematic Review, Network Meta-Analysis
Sponsor: Legacy
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.